/DRUG.CN
DRUG.CN Stock - Bright Minds Biosciences Inc.
Healthcare|BiotechnologyCNQ
$115.36+0.99%
+$1.13 (+0.99%) • Dec 23
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $126.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DRUG.CN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$114.21 – $116.51
TARGET (TP)$132.66
STOP LOSS$106.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.53
52W High$131.88
52W Low$33.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-73,357 | $-72,450 | $-6,037 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,813,822 | $-7,366,664 | $-14,742,164 | $-8,758,553 | $-469,358 |
| Net Income | $-2,801,946 | $-7,372,225 | $-15,187,718 | $-8,515,329 | $-485,945 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.65 | $-1.98 | $-6.15 | $-4.74 | $-0.38 |
Company Overview
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DRUG.CNBeat Rate
100%
Last 4 quarters
Avg Surprise
+44.5%
EPS vs Estimate
Beats / Misses
4/0
Last 12 quarters
Latest EPS
$-0.78
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q3 24
+72.3%
$-0.17vs$-0.60
Q1 25
+101.2%
$0.01vs$-0.60
Q2 25
+3.3%
$-0.42vs$-0.43
Q4 25
+1.2%
$-0.78vs$-0.78
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 24, 2025 | $-1.00 | — | — | — |
Q4 2025 | Dec 18, 2025 | $-0.78 | $-0.78 | +1.2% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.43 | $-0.42 | +3.3% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.60 | $0.01 | +101.2% | ✓ BEAT |
Q3 2024 | Sep 30, 2024 | $-0.60 | $-0.17 | +72.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | — | $0.05 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.13 | — | — |
Q1 2024 | Feb 12, 2024 | — | $-0.44 | — | — |
Q4 2023 | Dec 29, 2023 | — | $-0.41 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.39 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.56 | — | — |
Q1 2023 | Feb 7, 2023 | — | $-0.68 | — | — |
Q4 2022 | Dec 29, 2022 | — | $-0.98 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-1.12 | — | — |
Q2 2022 | May 16, 2022 | — | $-1.90 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-2.05 | — | — |
Q4 2021 | Dec 29, 2021 | — | $-0.24 | — | — |
Q3 2021 | Jul 17, 2021 | — | $-1.56 | — | — |
Q2 2021 | Jun 17, 2021 | — | $-0.65 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-1.14 | — | — |
Latest News
Loading news...
Frequently Asked Questions about DRUG.CN
What is DRUG.CN's current stock price?
Bright Minds Biosciences Inc. (DRUG.CN) is currently trading at $115.36 per share. The stock has moved +0.99% today.
What is the analyst price target for DRUG.CN?
No analyst price targets are currently available for this stock.
What sector is Bright Minds Biosciences Inc. in?
Bright Minds Biosciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the CNQ exchange.
What is DRUG.CN's market cap?
Bright Minds Biosciences Inc. has a market capitalization of $0.82 billion, making it a small-cap company.
Does DRUG.CN pay dividends?
No, Bright Minds Biosciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCL.CN
Cresco Labs Inc.
$1.55
Mkt Cap: $0.5B
EDT.TO
Spectral Medical Inc.
$1.26
Mkt Cap: $0.4B
EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.55
Mkt Cap: $0.3B
FRX.TO
Fennec Pharmaceuticals Inc.
$10.67
Mkt Cap: $0.3B
GUD.TO
Knight Therapeutics Inc.
$5.96
Mkt Cap: $0.6B
HITI.V
High Tide Inc.
$3.80
Mkt Cap: $0.3B
KSI.TO
Kneat.com, Inc.
$4.80
Mkt Cap: $0.5B
NGEN.V
NervGen Pharma Corp.
$6.94
Mkt Cap: $0.5B
VHI.TO
Vitalhub Corp.
$9.19
Mkt Cap: $0.5B
VRNO.NE
Verano Holdings Corp.
$1.61
Mkt Cap: $0.6B
Explore stocks similar to DRUG.CN for comparison